Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62

被引：0

作者：

Signorini, Claudia ^{[1
]}

Maffezzini, Massimo ^{[1
]}

机构：

[1] Fornaroli Hosp, Dept Urol, ASST Ovest Milanese, Via Donatore Sangue, Magenta, Italy

来源：

EUROPEAN UROLOGY | 2021年 / 79卷 / 05期

关键词：

TUMOR-LIKE LESIONS;

D O I：

10.1016/j.eururo.2021.01.034

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E135 / E136

页数：2

共 14 条

[1] Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62
Lindgren, Maria S.
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2021, 79 (05) : E137 - E137
[2] The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial
Lindgren, Maria S.
Bue, Peter
Azawi, Nessn
Blichert-Refsgaard, Linea
Sundelin, Maria O.
Dyrskjot, Lars
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2020, 78 (06) : 856 - 862
[3] Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskj?t, J?rgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press
Pradere, Benjamin
Basile, Giuseppe
Seisen, Thomas
EUROPEAN UROLOGY, 2023, 83 (04) : E105 - E106
[4] Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjot, Jorgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206-11
Lindgren, Maria S.
Jensen, Jorgen B.
EUROPEAN UROLOGY, 2023, 83 (04) : E107 - E108
[5] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Sahoo, Suman
Pandey, Abhishek
Mandal, Swarnendu
Das, Manoj Kumar
Nayak, Prasant
EUROPEAN UROLOGY, 2023, 83 (02) : E47 - E47
[6] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Campodonico, Fabio
Mattioli, Francesca
Introini, Carlo
EUROPEAN UROLOGY, 2023, 83 (02) : E56 - E57
[7] Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. Eur Urol 2012;62:797-802
Garg, Manish
Goel, Apul
Prakash, Jai
EUROPEAN UROLOGY, 2013, 63 (01) : E6 - E6
[8] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Garg, Harshit
Nayak, Brusabhanu
Singh, Prabhjot
EUROPEAN UROLOGY, 2019, 75 (02) : E25 - E25
[9] Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52
Poletajew, Slawomir
Radziszewski, Piotr
Palou, Juan
EUROPEAN UROLOGY, 2017, 71 (01) : E29 - E30
[10] Reply to Manish Garg, Apul Goel and Jai Prakash's Letter to the Editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. Eur Urol 2012;62:797-802
Colombo, Renzo
Rocchini, Lorenzo
Suardi, Nazareno
Benigni, Fabio
Colciago, Giorgia
Bettiga, Arianna
Pellucchi, Federico
Maccagnano, Carmen
Briganti, Alberto
Salonia, Andrea
Rigatti, Patrizio
Montorsi, Francesco
EUROPEAN UROLOGY, 2013, 63 (01) : E7 - E8

← 1 2 →